Form 4 for PLYX Polaryx Therapeutics, Inc.
Accepted 2026-02-20 00:00:00 ET · period of report 2026-02-18 · accession 0001213900-26-018845 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-20 | 2026-02-18 | PLYX | Landis G. Michael | CFO, Dir | P - Purchase | $2.79 | +2,867 | 228.2K | +1% | +$7,999 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-18 | P | A | 2,867 | $2.79 | 228,225 | D | — | — |